36414-60-5

Upstream product

• 2430-99-1 1-phenyl-2-p-tolylethanone 

Downstream Products

• 116544-75-3 1-Phenyl-2-p-tolyl-2-p-tolyloxy-ethanone 
• 116544-74-2 2-(4-Chloro-phenoxy)-1-phenyl-2-p-tolyl-ethanone 
• 116544-73-1 6,7-Dimethyl-3-phenyl-2-p-tolyl-benzofuran 
• 116544-79-7 chloro-5 phenyl-2 p-tolyl-3 benzofuranne 
• 116544-80-0 methyl-5 phenyl-2 p-tolyl-3 benzofuranne 
• 16762-18-8 6,7-dimethyl-2-phenyl-3-p-tolyl-benzofuran 
• 55082-72-9 5,7-dimethyl-2-phenyl-3-p-tolyl-benzofuran 
• 35307-35-8 2-phenyl-3-(4-methylphenyl)benzofuran 
• 147001-00-1 4,5-Dihydroxy-1,5-diphenyl-4-(p-tolyl)-imidazolidin-2-on 
• 147001-06-7 5-Hydroxy-1,5-diphenyl-4-(p-tolyl)-imidazolin-2-on 
• 147000-94-0 1,5-Diphenyl-4-p-tolyl-1,3-dihydro-imidazol-2-one 
• 35307-30-3 2-Phenoxy-1-phenyl-2-p-tolyl-ethanone 
• 116544-76-4 2-(2,4-Dimethyl-phenoxy)-1-phenyl-2-p-tolyl-ethanone 
• 408527-51-5 2-Amino-1-phenyl-2-p-tolyl-ethanone 

Relevant academic research and scientific papers

Concerning the reaction mechanism of the hydantoin synthesis according to Biltz, I: Proof of the intermediates

The reaction mechanism of the rearrangement occurring during the hydantoin synthesis according to Biltz, proposed by Butler and Leitch, has been ascertained. The intermediate 3a, already proposed by Biltz, could be isolated out of the reaction mixture. Th

SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES

The invention provides compounds represented by the structural formula (1): wherein R1, R2, R3, R4, R5, R6 are as defined in the claims. The compounds are inhibitors of nucleases, and are useful in particular in a method of treatment and/or prevention of proliferative diseases, neurodegenerative diseases, and other genomic instability associated diseases.